KLENTZ- florfenicol, terbinafine, mometasone furoate solution
Klentz by
Drug Labeling and Warnings
Klentz by is a Animal medication manufactured, distributed, or labeled by Aurora Pharmaceutical, Inc. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
- DESCRIPTION:
- INDICATIONS:
-
DOSAGE AND ADMINISTRATION:
Klentz should be administered by veterinary personnel.
Wear eye protection when administering Klentz. (see Human Warnings, Precautions, Post-Approval Experience).
Splatter may occur if the dog shakes its head following administration. Persons near the dog during administration should also take steps to avoid ocular exposure.
Shake before use.
Verify the tympanic membrane is intact prior to administration. (see Contraindications, Precautions, Post-Approval Experience).
Administer one dose (1 dropperette) per affected ear.
1. Clean and dry the external ear canal before administering the product.
2. Verify the tympanic membrane is intact prior to administration.
3. Remove single dose dropperette from the package.
4. While holding the dropperette in an upright position, twist the cap to open the dropperette. The cap does not come off the dropperette.
5. Insert the tapered tip of the dropperette into the affected external ear canal and squeeze to instill the entire contents (1 mL) into the affected ear.
6. Gently massage the base of the ear to allow distribution of the solution.
Restrain the dog to minimize post application head shaking to reduce potential for splatter of product and accidental eye exposure in people and dogs (see Post-Approval Experience).
7. Repeat with other ear as prescribed.
8. The duration of the effect should last 30 days. Cleaning the ear after dosing may affect product effectiveness.
-
CONTRAINDICATIONS:
Do not use in dogs with known tympanic membrane perforation (see Precautions).
Klentz is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate.
-
WARNINGS:
Human Warnings:Klentz may cause eye injury and irritation (see Precautions, Post-Approval Experience).
If contact with eyes occurs, flush copiously with water for at least 15 minutes. If irritation persists, contact a physician.
Humans with known hypersensitivity to any of the active ingredients in Klentz should not handle this product.
Not for use in humans. Keep this and all drugs out of the reach of children. Avoid skin contact. In case of accidental ingestion by humans, contact a physician immediately.
-
PRECAUTIONS:
For use in dogs only. Do not use in cats (see Post-Approval Experience).
Wear eye protection when administering Klentz and restrain the dog to minimize post application head shaking. Reducing the potential for splatter of product will help prevent accidental eye exposure in people and dogs and help to prevent ocular injury (see Dosage and Administration, Human Warnings, Post-Approval Experience).
Proper patient selection is important when considering the benefits and risks of using Klentz. The integrity of the tympanic membrane should be confirmed before administering the product.
Florfenicol, terbinafine, and mometaone furoate otic solution has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment.
Signs of internal ear disease such as head tilt, vestibular signs, ataxia, nystagmus, facial paralysis, and keratoconjunctivitis sicca have been reported (see Post-Approval Experience) with the use of florfenicol, terbinafine, and mometasone furoate otic solution.
Do not administer orally.
Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see Animal Safety).
Use with caution in dogs with impaired hepatic function (see Animal Safety).
The safe use of Klentz in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.
-
ADVERSE REACTIONS:
In a field study conducted in the United States (see Effectiveness), there were no directly attributable adverse reactions in 146 dogs administered florfenicol, terbinafine, and mometasone furoate otic solution.
-
POST-APPROVAL EXPERIENCE (2019):
The following adverse events are based on post-approval adverse drug experience reporting for florfenicol, terbinafine, and mometasone furoate otic solution. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.
In humans, accidental exposure leading to corneal ulcers and other ocular injuries such as eye irritation and redness have been reported. Exposure occurred when the dog shook its head after application of florfenicol, terbinafine, and mometasone furoate otic solution. Skin irritation has also been reported.
In dogs, the adverse events reported are presented below in decreasing order of reporting frequency:
Ear discharge, head shaking, ataxia, internal ear disorder (head tilt and vestibular), deafness, emesis, nystagmus, pinnal irritation and ear pain, keratoconjunctivitis sicca, vocalization, corneal ulcer, cranial nerve disorder (facial paralysis), tympanic membrane rupture.Klentz (florfenicol, terbinafine, and mometasone furoate) otic solution is not approved for use in cats. The adverse events reported following extra-label use in cats are presented below in decreasing order of reporting frequency:
Ataxia, anorexia, internal ear disorder (head tilt and vestibular), Horner’s syndrome (third eyelid prolapse and miosis), nystagmus, lethargy, anisocoria, head shake, emesis, tympanic rupture, and deafness. -
CONTACT INFORMATION:
To report suspected adverse drug experiences, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Aurora Pharmaceutical at 1-888-215-1256.
For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae
-
Information for Dog Owners:
Owners should be aware that adverse reactions may occur following administration of Klentz and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge (see Post-Approval Experience). Owners should be advised to contact their veterinarian if any of the above signs are observed.
Owners should also be informed that splatter may occur if the dog shakes its head following administration of Klentz which may lead to ocular exposure. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Owners should be careful to avoid ocular exposure (see Precautions, Post-Approval Experience).
-
PHARMACOLOGY:
Klentz otic solution is a fixed combination of three active substances: florfenicol (antibacterial), terbinafine (antifungal), and mometasone furoate (steroidal anti-inflammatory). Florfenicol is a bacteriostatic antibiotic which acts by inhibiting protein synthesis. Terbinafine is an antifungal which selectively inhibits the early synthesis of ergosterol. Mometasone furoate is a glucocorticosteroid with anti-inflammatory activity.
-
MICROBIOLOGY:
The compatibility and additive effect of each of the components in CLARO solution was demonstrated in a component effectiveness and non-interference study. An in vitro study of organisms collected from clinical cases of otitis externa in dogs enrolled in the clinical effectiveness study determined that florfenicol and terbinafine hydrochloride inhibit the growth of bacteria and yeast commonly associated with otitis externa in dogs. No consistent synergistic or antagonistic effect of the two antimicrobials was demonstrated. The addition of mometasone furoate to the combination did not impair antimicrobial activity to any clinically significant extent. In a field study (see Effectiveness), at least 10 isolates from successfully treated cases were obtained for S. pseudintermedius and M. pachydermatis.
-
EFFECTIVENESS:
In a well-controlled, double-masked field study, florfenicol, terbinafine, and mometasone furoate otic solution was evaluated against a vehicle control in 221 dogs with otitis externa. One hundred and forty six dogs were treated with florfenicol, terbinafine, and mometasone furoate otic solution and 75 dogs were treated with the vehicle control. All dogs were evaluated for safety. Treatment (1 mL) was administered once on Day 0 to the affected ear(s). Prior to treatment, the ear(s) was cleaned with saline. The dogs were evaluated on Days 0, 7, 14, and 30. Blood work and urinalysis were obtained on Day 0 pre-treatment and Day 30 at study completion. Four clinical signs associated with otitis externa were evaluated: erythema, exudate, swelling, and ulceration. Success was based on clinical improvement at Day 30. Of the 183 dogs included in the effectiveness evaluation, 72.5% of dogs administered florfenicol, terbinafine, and mometasone furoate otic solution were successfully treated, compared to 11.1% of the dogs in the vehicle-control group (p = 0.0001).
-
ANIMAL SAFETY:
In a target animal safety study, florfenicol, terbinafine, and mometasone furoate otic solution was administered aurally to 12-week-old Beagle puppies (4 dogs/sex/group) at 0X, 1X, 3X, and 5X the recommended dose once every 2 weeks for a total dosing period of 28 days (3 times the treatment duration). No clinically relevant treatment-related findings were noted in hearing tests, body weight, weight gain, or food consumption. Florfenicol, terbinafine, and mometasone furoate otic solution administration was associated with post-treatment ear wetness or clear aural exudate, increased absolute neutrophil count, decreased absolute lymphocyte and eosinophil counts, suppression of the adrenal cortical response to ACTH-stimulation, decreased adrenal weight and atrophy of the adrenal cortex, increased liver weight with hepatocellular enlargement/cytoplasmic change, and decreased thymus weight. Other potentially treatment-related effects included mild changes to AST, total protein, inorganic phosphorus, creatinine, and calcium.
- STORAGE INFORMATION:
-
HOW SUPPLIED:
Klentz solution is supplied in a single-use dropperette in a blister.
Each dropperette contains one 1 mL dose.
Klentz is available in cartons of two, twelve, or twenty-four dropperettes.Manufactured by:
Aurora Pharmaceutical, Inc.
Northfield, MN 55057
1-888-215-1256 www.aurorapharmaceutical.comApproved by FDA under ANADA # 200-829
-
Principal Display Panel - 1 mL Carton Label
KLENTZ™
(florfenicol, terbinafine,
mometasone furoate)Otic Solution for use in dogs only
Do Not Use in Cats.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-829
Net Contents: 2 x 1 mL single dose dropperettes
See package insert for complete safety and administration information prior to use.
IN 40-1815 Rev. 11/2025
KLENTZ™
(florfenicol, terbinafine,
mometasone furoate)Otic Solution for use in dogs only
Do Not Use in Cats.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-829
Net Contents: 12 x 1 mL single dose dropperettes
IN 40-1816 Rev. 11/2025
KLENTZ™
(florfenicol, terbinafine,
mometasone furoate)Otic Solution for use in dogs only
Do Not Use in Cats.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-829
Net Contents: 24 x 1 mL single dose dropperettes
IN 40-1829 Rev. 11/2025
-
INGREDIENTS AND APPEARANCE
KLENTZ
florfenicol, terbinafine, mometasone furoate solutionProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 51072-122 Route of Administration AURICULAR (OTIC) Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength FLORFENICOL (UNII: 9J97307Y1H) (FLORFENICOL - UNII:9J97307Y1H) FLORFENICOL 16.6 mg in 1 mL TERBINAFINE (UNII: G7RIW8S0XP) (TERBINAFINE - UNII:G7RIW8S0XP) TERBINAFINE 14.8 mg in 1 mL MOMETASONE FUROATE (UNII: 04201GDN4R) (MOMETASONE - UNII:8HR4QJ6DW8) MOMETASONE FUROATE 2.2 mg in 1 mL Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 51072-122-00 2 in 1 CARTON 1 1 in 1 BLISTER PACK 1 1 mL in 1 TUBE 2 NDC: 51072-122-01 12 in 1 CARTON 2 1 in 1 BLISTER PACK 2 1 mL in 1 TUBE 3 NDC: 51072-122-02 24 in 1 CARTON 3 1 in 1 BLISTER PACK 3 1 mL in 1 TUBE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200829 01/19/2026 Labeler - Aurora Pharmaceutical, Inc (832848639) Establishment Name Address ID/FEI Business Operations Aurora Pharmaceutical, Inc 832848639 manufacture
© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.